Masimo (NASDAQ:MASI) Price Target Raised to $180.00

Masimo (NASDAQ:MASI) had its price objective upped by Piper Sandler from $165.00 to $180.00 in a research note published on Wednesday morning,Benzinga reports. They currently have an overweight rating on the medical equipment provider’s stock.

A number of other research firms have also weighed in on MASI. BTIG Research increased their price objective on shares of Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research report on Wednesday. Finally, Raymond James raised Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 price objective for the company in a report on Wednesday. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $163.67.

Masimo Price Performance

NASDAQ MASI opened at $162.41 on Wednesday. The stock’s fifty day moving average price is $133.52 and its 200 day moving average price is $126.00. Masimo has a 1 year low of $81.82 and a 1 year high of $173.90. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.15. The company has a market cap of $8.64 billion, a price-to-earnings ratio of 112.01 and a beta of 0.97.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.84 by $0.14. The firm had revenue of $504.60 million during the quarter, compared to analysts’ expectations of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period last year, the business posted $0.63 earnings per share. As a group, equities research analysts forecast that Masimo will post 4.04 earnings per share for the current year.

Institutional Investors Weigh In On Masimo

Hedge funds have recently modified their holdings of the company. NBC Securities Inc. raised its holdings in Masimo by 47.1% in the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 73 shares during the period. GAMMA Investing LLC raised its stake in shares of Masimo by 75.0% during the 2nd quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock worth $33,000 after buying an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in shares of Masimo by 133.3% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 200 shares in the last quarter. HHM Wealth Advisors LLC grew its stake in Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock valued at $79,000 after acquiring an additional 125 shares during the period. Finally, Lazard Asset Management LLC increased its holdings in Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock worth $85,000 after acquiring an additional 573 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.